Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020
Research

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Marie JaspardComments to Author , Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, and Valerie Pourcher
Author affiliations: Sorbonne Université, Paris, France (M. Jaspard, H. Guillot, N. Veziris, B. Bodaghi, E. Caumes, V. Pourcher); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris (M. Jaspard, H. Guillot, E. Caumes, V. Pourcher); Assistance Publique – Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris (N. Butel, B. Bodaghi); Groupe Hospitalier Paris Saint Joseph, Paris (N. El Helali, G. Petitjean); Bligny Medical Center, Briis sous Forges, France (D. Marigot-Outtandy); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris (G. Peytavin); Université Paris Diderot, Sorbonne Paris Cité, Paris (G. Peytavin); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires de l’Est Parisien, Paris (N. Veziris); Institut Pierre Louis Institute d’Épidémiologie et de Santé Publique, Paris (P. Flandre, E. Caumes, V. Pourcher)

Main Article

Table 3

Characteristics of 14 patients who experienced optic neuropathy after linezolid treatment for multidrug-resistant tuberculosis, Pitié-Salpêtrière Hospital, Paris, France, 2011–2016*

Patient age, y/sex, Fundus examination Visual color† Visual field Involvement Other Linezolid duration, mo Months from start of linezolid to onset of optic neuropathy Reversibility after linezolid withdrawal
37/M
 Papillary edema
 Tritanopia
 BSE
 B
 None
 3.4
 0.0
 No
42/M
 WNL
 Tritanopia
 Aciform scotoma
 B
 None
 13.5
 1.4
 No
20/M
 WNL
 Tritanopia
 WNL
 B
 None
 18.5
 1.6
 Yes
40/M
 WNL
 Tritanopia
 BSE
 B
 Optic neuropathy confirmed by VEP
 15.3
 14.6
 Yes
48/M
 WNL
 Tritan
 BSE
 B
 None
 5.7
 9.3
 No
43/M
 WNL
 Tritanopia
 NA
 U
 None
 11.6
 17.9
 Yes
40/M
 WNL
 Tritanopia
 BSE
 U
 None
 18
 NA
 Yes
39/M
 WNL
 Tritanopia
 BSE
 B
 None
 23.1
 15.4
 Yes
42/M
 WNL
 Tritanopia
 BSE
 B
 None
 19.4
 5.2
 Yes
40/M
 WNL
 Tritanopia
 NA
 B
4.4
 1.0
 No
34/M
 Papillary edema
 Tritanopia
 BSE
 B
 Optic neuropathy confirmed by VEP
 16.6
 15.1
 Yes
21/M
 Papillary edema
 Tritanopia
 Scotoma
 B
 Optic neuropathy confirmed by VEP
 7.1
 8.2
 Yes
23/F
 Hyperemia of optical nerve
 Tritanopia
 BSE
 B
 None
 NA
 10.2
 Yes
30/M Hyperemia of optical nerve Tritan BSE B None 19.1 16.2 Yes

*B, bilateral; BSE, blind spot enlargement; NA, not available; U, unilateral, VEP, visual evoked potential; WNL, within normal limits.
†Tritan, common blue–yellow color blindness.; tritarnopia, blue–yellow confusion typical in patients with optic neuropathies.

Main Article

Page created: June 12, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external